ArticleGenomics & informatics2026
AMP-CapsNet: a multi-view feature fusion approach for antimicrobial peptide prediction using capsule networks.
Article in Genomics & informatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Antimicrobial peptides (AMPs) are universally found in both intracellular and extracellular settings and have significant antibiotic-resistant bacteria are becoming a bigger problem. In medical laboratories, it has shown notable anti-bacterial effectiveness in treating diabetic foot infections and related issues. New medication development frequently targets (AMPs), which are certainly ensuing components of adaptive immune system. The findings of this research employs deep learning to identify antibiotic activity. Numerous computational methods have been established to detect antimicrobial peptides via deep learning algorithms. We introduced a novel deep learning approach called antimicrobial peptides using Capsule Neural Network (AMP-CapsNet) to precisely forecast them and evaluated its efficacy against deep learning and baseline models. AMPs prediction using capsule neural networks, a type of next generation neural network, to build prediction models. Additionally, we utilized Amino Acid Composition (AAC) for effective features encoded method and as well as dipeptide composition (DPC). Every model underwent independent cross-validation and external testing. The findings indicate that the enhanced AMP-CapsNet deep learning model surpassed its counterparts, achieving an accuracy of 97.29% and an AUC score of 98.91% on the test set using with dipeptide Composition (DPC). The proposed AMP-CapsNet demonstrates superior performance of the testing set achieved accuracy 97.29% score with DPC and accuracy 84.42% score with AAC approach. Consequently, the technique we advocate is anticipated to enhance the accuracy of antimicrobial peptide predictions in the future. By producing powerful peptides for medication development and application, this study advances deep learning-based AMP drug discovery approaches. This finding has important ramifications for how biological data is processed and how pharmacology is calculated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.